Blackstone Tactical Opportunities Hires Joseph Cassanelli as Senior Managing Director Focused on Financial Services Sector Investments
Chris James, Global Head of Tac Opps, said: "Joe's deep expertise and relationships in the financial services sector make him an ideal addition to Tac Opps – as we continue to seek to deliver differentiated performance for our investors. We believe our scale and flexible capital are particularly well suited for today's market environment, and look forward to working with Joe to continue serving as a trusted capital solutions provider to businesses in financial services and beyond."
Joseph Cassanelli added: "I am thrilled to join Blackstone Tactical Opportunities, which has built a well-deserved reputation for creativity and innovation as a pioneer in hybrid capital with exceptional investment professionals. I look forward to providing bespoke capital solutions in partnership with outstanding management teams and companies across the financial services sector."
Mr. Cassanelli spent more than two decades at Lazard, serving as a trusted strategic advisor to a broad range of global financial institutions. He has advised on more than half a trillion dollars of transactions, including many of the largest and most complex mergers, acquisitions, and strategic restructuring transactions in financial services. This included Blackstone's IPO and C-Corp conversion, and numerous financial services transactions for Tac Opps and insurance-related transactions for Blackstone Credit & Insurance. He also served as Chairman of Lazard's U.S. Fairness Opinion Committee. Prior to joining Lazard in 2002, Mr. Cassanelli spent several years at Wasserstein Perella & Co. and Deloitte.
Blackstone launched its Tactical Opportunities platform in 2012 – a strategy the firm pioneered – to invest across the landscape of private investment opportunities outside of traditional private equity and private credit. Tac Opps today has $34 billion of assets under management and is the largest hybrid capital solutions platform in the world. The Tac Opps team invests globally across asset classes, industries, and geographies, utilizing bespoke and innovative structures to seek to deliver compelling risk-adjusted returns by identifying and executing on attractive, differentiated investment opportunities.
Blackstone announced in 2023 the record close of Blackstone Tactical Opportunities Fund IV ("BTO IV"), which it is currently investing. Including other single-investor vehicles pursuing the same strategy, the combined BTO IV platform is currently expected to have nearly $10 billion of new capital in its fourth fundraising vintage. This is substantially higher than the BTO III platform and the largest-ever vintage of its kind. Marquee investments in BTO IV include CoreWeave, a specialized provider of critical cloud infrastructure pioneering the AI revolution, and the music royalty platform Recognition Music Group (f/k/a Hipgnosis).
About BlackstoneBlackstone is the world's largest alternative asset manager. Blackstone seeks to deliver compelling returns for institutional and individual investors by strengthening the companies in which the firm invests. Blackstone's nearly $1.2 trillion in assets under management include global investment strategies focused on real estate, private equity, credit, infrastructure, life sciences, growth equity, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616187687/en/
Contacts
Matt AndersonMatthew.Anderson@blackstone.com 518-248-7310
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Guggenheim Reiterates a Buy Rating on AbbVie (ABBV) With a $216 PT
AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) with a price target of $216.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported that net revenues in Q1 reached $13.343 billion, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. Global net revenues for the quarter for the Immunology portfolio rose to $6.264 billion, reflecting a growth of 16.6% on a reported basis or 18.1% on an operational basis. AbbVie Inc. (NYSE:ABBV) also experienced growth in global net revenues in the Neuroscience portfolio to $2.282 billion, reflecting a 16.1% increase on a reported basis or 17% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) ('Vaalco' or the 'Company') today announced the timing of its second quarter 2025 earnings release and conference call. The Company will issue its second quarter 2025 earnings release on Thursday, August 7, 2025 after the close of trading on the New York Stock Exchange and host a conference call to discuss its financial and operational results on Friday morning, August 8, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time and 3:00 p.m. London Time.) Interested parties in the United States may participate toll-free by dialing (833) 685-0907. Interested parties in the United Kingdom may participate toll-free by dialing 08082389064. Other international parties may dial (412) 317-5741. Participants should ask to be joined to the 'Vaalco Energy Earnings Conference Call.' This call will also be webcast on VAALCO's website at An audio replay will be available on the Company's website following the call. About Vaalco Vaalco, founded in 1985 and incorporated under the laws of Delaware, is a Houston, Texas, USA based, independent energy company with a diverse portfolio of production, development and exploration assets across Gabon, Egypt, Côte d'Ivoire, Equatorial Guinea, Nigeria and Canada. For Further Information Vaalco Energy, Inc. (General and Investor Enquiries) +00 1 713 543 3422 Website: Al Petrie Advisors (US Investor Relations) +00 1 713 543 3422 Al Petrie / Chris Delange Buchanan (UK Financial PR) +44 (0) 207 466 5000 Ben Romney / Barry Archer Vaalco@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data